13,711 Shares in Certara, Inc. (NASDAQ:CERT) Acquired by Capstone Investment Advisors LLC

Capstone Investment Advisors LLC bought a new position in shares of Certara, Inc. (NASDAQ:CERTFree Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,711 shares of the company’s stock, valued at approximately $245,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CERT. Pacer Advisors Inc. boosted its stake in Certara by 1,704.0% in the 4th quarter. Pacer Advisors Inc. now owns 12,754 shares of the company’s stock worth $224,000 after purchasing an additional 12,047 shares during the period. Trust Point Inc. purchased a new stake in Certara in the 4th quarter worth approximately $320,000. Advisors Preferred LLC purchased a new stake in Certara in the 4th quarter worth approximately $2,419,000. Louisiana State Employees Retirement System purchased a new stake in Certara in the 4th quarter worth approximately $943,000. Finally, New York State Common Retirement Fund lifted its position in Certara by 6.8% in the 4th quarter. New York State Common Retirement Fund now owns 239,853 shares of the company’s stock worth $4,219,000 after buying an additional 15,277 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Analysts Set New Price Targets

CERT has been the subject of a number of research analyst reports. Barclays cut their target price on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, June 28th. JMP Securities reiterated a “market perform” rating on shares of Certara in a research report on Wednesday. Finally, KeyCorp upgraded shares of Certara from a “sector weight” rating to an “overweight” rating and set a $23.00 target price for the company in a research report on Wednesday, April 10th. Seven research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $19.81.

Get Our Latest Report on Certara

Certara Stock Down 1.0 %

Certara stock opened at $13.88 on Thursday. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of -35.59, a P/E/G ratio of 4.93 and a beta of 1.52. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.26 and a quick ratio of 3.26. Certara, Inc. has a fifty-two week low of $11.81 and a fifty-two week high of $19.87. The firm has a fifty day moving average price of $15.58 and a two-hundred day moving average price of $16.70.

Certara (NASDAQ:CERTGet Free Report) last released its earnings results on Tuesday, May 7th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. The firm had revenue of $96.65 million for the quarter, compared to analyst estimates of $94.48 million. As a group, analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Company Profile

(Free Report)

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

Featured Stories

Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERTFree Report).

Institutional Ownership by Quarter for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.